


Cambridge Core

Acta Neuropsychiatrica



SPECIAL ISSUE: Progress in Psychopharmacology



Giulia Treccani
University of Marburg
GERMANY

GUEST-EDITORS

Todd Gould
University of Maryland School of Medicine
USA



CALL FOR PAPERS

In recent years, the field of psychopharmacology has witnessed rapid developments, with the potential to fundamentally transform the landscape of treatment options for neuropsychiatric disorders. Among the most notable advancements are for example the emergence of a rapid-acting antidepressant, ketamine, offering new hope that this finding will lead to further discovery and development of new possibilities for patients with depression.

Acta Neuropsychiatrica announces a call for submissions to a special issue titled "**Progress in Psychopharmacology**," dedicated to showcasing the latest advancements in the field. This issue aims to cover a wide range of topics, from preclinical science to cutting-edge overviews of new drugs in clinical trials to comprehensive pharmacoepidemiological studies, underscoring their significance in the treatment of neuropsychiatric disorders.

We invite researchers to contribute original articles and review papers that provide fundamental insights into both clinical and preclinical studies, with a particular emphasis on novel findings in drug mechanisms of action, development, and treatment outcomes.

Final submissions are due **August 1st 2024** on the Journal submission site: <https://mc.manuscriptcentral.com/acn>

Express interest in the issue here: <https://forms.office.com/e/mK8Jppbbu7>

All submissions will be peer-reviewed.



@scnpjjournal



<http://facebook.com/actaneuropsychiatrica>



<https://coreblog.cambridge.org>

<https://cambridge.org/neu>



Scandinavian College of
Neuropsychopharmacology



CAMBRIDGE
UNIVERSITY PRESS

Cambridge Core

Acta Neuropsychiatrica

EDITOR-IN-CHIEF

Gregers Wegener, Aarhus
University, Denmark

2022 IMPACT FACTOR: 3.8


SCOPE

Acta Neuropsychiatrica is an international journal focussing on translational neuropsychiatry. It publishes high-quality original research papers and reviews. The journal's scope specifically highlights the pathway from discovery to clinical applications, healthcare and global health that can be viewed broadly as the spectrum of work that marks the pathway from discovery to global health. The steps of translation that are within the scope include:

- 1) fundamental discovery,
- 2) bench to bedside,
- 3) clinical trials
- 4) translation to clinical guidelines,
- 5) health policy and usage, and
- 6) global health.

Research covering molecular biology, genetics, pharmacology, imaging and epidemiology is welcome.

FREE SAMPLE CONTENT



INDEXED IN

- Embase (*Elsevier*)
- Journal Citation Reports/Science Edition (*Clarivate Analytics*)
- PsycINFO/Psychological Abstracts (*APA*)
- PubMed/MEDLINE
- Science Citation Index Expanded (*Clarivate Analytics*)
- Scopus (*Elsevier*)

Complete list: <https://cambridge.org/neu>

ACCESS KEY ARTICLES FOR FREE ONLINE

<https://cambridge.org/neu-free>



@scnpjjournal



<http://facebook.com/actaneuropsychiatrica>



<https://coreblog.cambridge.org>

<https://cambridge.org/neu>



Scandinavian College of
Neuropsychopharmacology



CAMBRIDGE
UNIVERSITY PRESS